SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Compugen to Present Predictive Methodology for Discovery of Novel Immune Checkpoints at the Washington BioLeaders Forum

[January 22, 2014]

Compugen to Present Predictive Methodology for Discovery of Novel Immune Checkpoints at the Washington BioLeaders Forum

TEL AVIV, Israel --(Business Wire)--

Compugen (News - Alert) Ltd. (NASDAQ: CGEN) today announced that Dr. John Hunter of Compugen USA, Inc. will present at the Washington BioLeaders Forum 2014 to be held next week in Washington, D.C. In his talk, which is scheduled for January 28 in the Phacilitate Immunotherapy Forum track, Dr. Hunter will demonstrate how Compugen has applied its predictive discovery platforms to identify novel immune checkpoints for targeted antibody immunotherapy in cancer. Validation data for reprsentative targets discovered by the Company will also be presented. Dr. Hunter is Site Head & Vice President, Antibody Research & Development at Compugen USA, Inc., a wholly owned subsidiary of Compugen Ltd.


The Immunotherapy Forum 2014, which in previous years was held in Barcelona, is an annual international conference focusing on key emerging trends in novel immunotherapeutic modalities, including checkpoint inhibitors, adoptive T-cell therapies, other cancer vaccine technologies and oncolytic virus therapeutics. This is the first year that the forum is being held as part of the annual Washington BioLeaders Forum.

About Compugen
Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com.


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy